As the US reduces its funding for global health research, a new study highlights that much of this money remains within wealthy countries. The research argues that the investments often lead to inventions that are later repurposed primarily for people in affluent, donor nations.
During Donald Trump’s second administration, significant policy shifts occurred, including the closure of the US Agency for International Development (USAID). Additionally, efforts were made to halt overseas sub-awards from the country’s National Institutes of Health (NIH).
These changes raise important questions about the future of global health research funding and its impact on low- and middle-income countries that often rely on US support.
https://sciencebusiness.net/news/r-d-funding/drug-development/global-health-rd-benefits-rich-countries-too-study-argues
